{"id":53354,"date":"2026-02-26T14:53:25","date_gmt":"2026-02-26T13:53:25","guid":{"rendered":"https:\/\/skan.clients.ideeal.ch\/?page_id=53354"},"modified":"2026-05-13T17:05:55","modified_gmt":"2026-05-13T15:05:55","slug":"about-skan","status":"publish","type":"page","link":"https:\/\/skan.com\/en\/company\/about","title":{"rendered":"About SKAN"},"content":{"rendered":"\r\n \r\n \r\n
\r\n
\r\n
\r\n
\r\n
\r\n \r\n
\r\n \"\" <\/figure>\r\n <\/div>\r\n <\/div>\r\n
\r\n
\r\n

About SKAN<\/h1>\r\n

We don\u2019t sell isolators. We deliver Grade A.<\/p>\r\n \r\n <\/span><\/span><\/span>\r\n Learn more<\/span>\r\n <\/a>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/div>\r\n <\/section>\r\n

<\/div>\r\n \r\n \r\n\n\n\t
\r\n\t\t
\r\n\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t

Since 1968, we have combined Swiss pioneering spirit with global technological leadership. As the world\u2019s leading provider of isolators, cleanroom equipment, and decontamination systems, we set standards where regulatory requirements, process reliability, and performance allow no compromises.<\/p>\n

Our technologies are used across Europe, North America, Japan, South Korea, and Singapore, where the highest regulatory standards apply. Based on our insights, one in three vaccines in our core markets is manufactured in a SKAN isolator. This trust is a commitment for us: we not only deliver equipment but also take responsibility for reliable performance in daily production from process consulting and qualification strategies to digital solutions across the entire lifecycle.<\/p>\n

Regulatory expertise as the foundation for planning reliability<\/h4>\n

SKAN\u2019s strength lies in the unique combination of Swiss precision, engineering excellence, and deep regulatory expertise. Our technologies and documentation concepts are consistently aligned with international regulations such as EU-GMP Annex 1, FDA requirements, and ISO standards. We do not see regulatory requirements as a burden, but as a foundation for accelerated approval processes, minimized compliance risk, and maximum planning reliability for our customers.<\/p>\n

Partnerships that go beyond projects<\/h4>\n

For decades, we have worked with leading biopharmaceutical companies and research institutions. Our systems are mission-critical to production success; accordingly, we design these relationships for the long term and in a spirit of partnership. SKAN remains responsible until the system is not only installed, but also qualified, accepted, and operating stably \u2014 and beyond that upon request.<\/p>\n

With around 1,500 employees across four continents, we combine global standards with local proximity. Our customers benefit from a single point of contact who understands their regulatory, technical, and cultural requirements.<\/p>\n

Rethinking aseptic production<\/h4>\n

New therapy modalities such as personalized cancer therapies, cell and gene therapies, and innovative vaccine platforms require flexible, safe, and efficient production processes. SKAN continuously advances its technologies toward higher automation, robot-assisted processes, and digitally supported production concepts. In this way, we support our customers not only in addressing current challenges but also on the path toward the production models of tomorrow.<\/p>\n\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t<\/section>\r\n\n\n

\r\n
\r\n
\r\n

Why SKAN?<\/h2>\r\n <\/header>\r\n
\r\n